MANE Veradermics, Inc
Pharmaceutical Preparations · NYSE · SEC CIK 1827635 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-11.7%
ROA-11.6%
ROIC (approx.)-13.2%
Asset turnover—
Leverage & solvency
Liabilities / assets1.3%
Debt / equity0.00x
Current ratio77.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.88x
Accruals ratio-1.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $62.06M | $23.28M |
| SG&A expense | $10.28M | $3.50M |
| Operating income | -$72.35M | -$26.78M |
| Interest expense | $0 | $585,000 |
| Pretax income | -$70.00M | -$26.49M |
| Income tax | $0 | $0 |
| Net income | -$70.00M | -$26.49M |
| EPS (basic) | -111.91 | -37.05 |
| EPS (diluted) | -111.91 | -37.05 |
| Weighted avg. shares (diluted) | 744,991 | 736,933 |
| Balance sheet | ||
| Cash & equivalents | $21.77M | $53.08M |
| Short-term investments | $120.10M | $0 |
| Current assets | $152.49M | $55.53M |
| PP&E, net | $22,000 | $0 |
| Total assets | $152.62M | $55.53M |
| Current liabilities | $9.15M | $4.72M |
| Total liabilities | $9.16M | $4.72M |
| Shareholders' equity | -$121.01M | -$48.48M |
| Shares outstanding | 749,760 | 736,933 |
| Cash flow statement | ||
| Operating cash flow | -$71.60M | -$23.69M |
| Capital expenditure | $24,000 | $0 |
| Free cash flow | -$71.63M | -$23.69M |
| Investing cash flow | -$118.86M | $0 |
| Financing cash flow | $159.14M | $60.48M |
| Stock-based compensation | $1.44M | $250,000 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.